Factor VII biosimilar - Genexine/Handok

Drug Profile

Factor VII biosimilar - Genexine/Handok

Alternative Names: GX-F7

Latest Information Update: 30 Sep 2013

Price : $50

At a glance

  • Originator Genexine
  • Developer Genexine; Handok Inc
  • Class Blood coagulation factors; Recombinant fusion proteins; Serine endopeptidases
  • Mechanism of Action Factor VII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 08 Sep 2013 Preclinical development is ongoing in South Korea
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
  • 31 Dec 2007 Genexine's Factor VII biosimilar licensed to Handok Pharmaceuticals in Asia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top